In this study, we demonstrate that FBXL2 is an E3 ubiquitin ligase targeting EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation to inhibit EGFR-driven NSCLC growth. This evidence concerns the gene FBXL2 and non-small cell lung carcinoma.